0 CHECKOUT

Portal Hypertension - Pipeline Review, H2 2015

  • ID: 3455158
  • September 2015
  • 69 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • Mezzion Pharma Co. Ltd.
  • MORE

Portal Hypertension - Pipeline Review, H2 2015

Summary

The report ‘Portal Hypertension - Pipeline Review, H2 2015’, provides an overview of the Portal Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • Mezzion Pharma Co. Ltd.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Portal Hypertension Overview

Therapeutics Development

Pipeline Products for Portal Hypertension - Overview

Pipeline Products for Portal Hypertension - Comparative Analysis

Portal Hypertension - Therapeutics under Development by Companies

Portal Hypertension - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Portal Hypertension - Products under Development by Companies

Portal Hypertension - Companies Involved in Therapeutics Development

Conatus Pharmaceuticals Inc.

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Mezzion Pharma Co. Ltd.

Ono Pharmaceutical Co., Ltd.

Portal Hypertension - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

emricasan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GR-MD-02 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ONO-1266 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Px-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Portal Hypertension - Recent Pipeline Updates

Portal Hypertension - Dormant Projects

Portal Hypertension - Discontinued Products

Portal Hypertension - Product Development Milestones

Featured News & Press Releases

Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension

Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Portal Hypertension, H2 2015

Number of Products under Development for Portal Hypertension - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2015

Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2015

Portal Hypertension - Pipeline by Gilead Sciences, Inc., H2 2015

Portal Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015

Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2015

Portal Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Portal Hypertension Therapeutics - Recent Pipeline Updates, H2 2015

Portal Hypertension - Dormant Projects, H2 2015

Portal Hypertension - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Portal Hypertension, H2 2015

Number of Products under Development for Portal Hypertension - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Conatus Pharmaceuticals Inc.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Mezzion Pharma Co. Ltd.
Ono Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx